deltatrials
Unknown PHASE1 INTERVENTIONAL NCT00100074

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Safety and Tolerability Study of Sublingual Lobeline

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Amphetamine-Related Disorders
Interventions Lobeline
Updated 5 times since 2017 Last updated: Jan 10, 2017 Started: Sep 30, 2004 Completion: Apr 30, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Amphetamine-Related Disorders and is currently ongoing. National Institute on Drug Abuse (NIDA) leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE1

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute on Drug Abuse (NIDA)
Data source: National Institute on Drug Abuse (NIDA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations